The haemodynamic effect of practolol, a cardioselective beta-adrenergic receptor blocker, has been studied in I8 patients during the acute phase of myocardial infarction. After intravenous administration of IO or 20 mg, a negative chronotropic effect was observed which was associated with a moderate decrease in cardiac output but no change in stroke volume.
As a result of experimental studies, Lands et al. (I967) have modified the classification proposed by Ahlquist (I948) to the effect that beta-adrenergic receptors do not constitute a homogeneous group and in order to account for certain experimental observations it is necessary to distinguish between beta-i receptors that subserve lipolysis and the myocardium and beta-2 receptors that subserve bronchodilatation and peripheral vasodilatation.
Experimental studies have shown that practolol is capable of selectively blocking the inotropic and chronotropic effects of catecholamines (Parratt and Wadsworth, I969, I970) , that is, it can selectively act on the beta-adrenergic myocardial receptors. It does not block the beta-2 receptor nor does it inhibit peripheral and coronary vasodilatation induced by isoprenaline (Ross and Jorgensen, 1970;  Bussmann, Rauh, and Krayenbuehl, 1970; Dunlop and Shanks, I968) .
The remarkable antiarrhythmic properties of beta-adrenergic receptor blocking agents are well known and they have potential uses in the treatment of ventricular and supraventricular disturbances during the acute phase of myocardial infarction whenever these disturbances are associated with catecholamine release (Ceremuzynski, Staszewska- Barczak, and Herbaczynska-Cedro, I969; Richardson, I963; Han, I969) . However, the Received 14 December 1971. use of propranolol during the acute stage of myocardial infarction is restricted on account of its depressant effects on myocardial function.
Experimental (Ceremuzynski et al., I969; Dunlop and Shanks, I968) and human (Gibson, Hoy, and Sowton, 1970; Jewitt, Mercer, and Shillingford, I969) studies have shown that practolol is an effective antiarrhythmic agent in protecting the heart from ventricular and supraventricular disturbances at doses of 5 to 25 mg without any noticeable side effects (Sowton et al., I968; Jewitt et al., I969) .
This study was designed to investigate the haemodynamic effects of practolol during acute myocardial infarction and to evaluate its potential in the treatment of dysrhythmias.
Patients and methods
The haemodynamic effects of practolol were studied in i8 patients who had sustained acute myocardial infarctions within the previous 72 hours. The diagnosis of infarction was made in all cases from a typical clinical history, a Q wave indicating necrosis, and a clear rise in serum enzyme levels. In all patients pain had disappeared before catheterization. All the patients were of a physical and mental state to understand the nature of the investigation and all of them assented to take part in the study.
Patients with sinus bradycardia lower than 6o or with atrioventricular block or those in a state of shock were excluded from the study. On the other hand, 6 patients presenting signs of left ventricular insufficiency (gallop rhythm, crepitation, and/or radiological signs of pulmonary oedema) were included. dp/dt and the left ventricular dp/dt (George, Taylor, and In all patients, pressure, blood flow, and blood gas measurements were taken during a control period and then IO minutes after injection of IO mg practolol into the pulmonary artery and 20 minutes after a further injection of IO mg.
The difference between the control values and these recorded after administration of the drug were compared using Student's t test for paired samples.
Results
All the results (mean + SEM) are presented in Tables I, 2 , 3, and 4. Heart rate fell from a mean of 8o08 + 3-8 to 72-9 ± 2-9 beats a minute I0 minutes after administration of I0 mg practolol, representing a 9 per cent (P <o-ooi) reduction (Fig. I ). After the administration of 20 mg the heart rate remained unchanged. There was a positive correlation between the control values for heart rate and the percentage reduction of heart rate (r = o-63). Cardiac index fell slightly from 2-77 ± 0oI5 L/min/m2 to 2-48 ± 0oI5 1./min/m2 (P < o oi) though injection of a further io mg did not cause any additional reduction (final very slightly and to an insignificant extent (Fig. 3) while the external work index clearly fell from 4240 g m/min/m2 to 3640 g m/min/ m2 (P < o-oi). There was no further reduction after 20 mg. The systolic ejection rate was not altered since the stroke index and the systolic ejection time remained unchanged. The maximum first derivative of aortic pressure (dp/dt Ao) (Fig. 3) fell significantly from 905±88 to 8i8 ±82 mmHg/sec (P <o os). A statistically significant correlation was found between the percentage fall in heart rate and the percentage lowering of aortic dp/dt (r = 0-59).
The tension time index per beat remained unchanged after administration of both I0 mg and 20 mg practolol (Fig. 4) . By contrast, the tension time index per minute fell from 2307± I42 to 2094±II3 mmHg sec/mi (P <o0o5) . No further reduction was observed after the administration of 20 mg practolol (final value I987 ± 88 mmHg sec/min).
The arterial oxygen partial pressure did not change after io mg practolol (Table 3) though it increased perceptibly and significantly (P <ooi) after 20 mg practolol. The arterial carbon dioxide pressure and the pH were not altered. The oxygen content of arterial blood showed no change after IO mg and 20 mg (Table 3) . By contrast, the pulmonary arterial oxygen content (CvO2) fell conspicuously after IO mg and 20 mg (P < ooi). This gave rise to a significant increase in the arteriovenous difference from 4-92 ± 0-34 to 5-78 ± 045 and to 6-os5±03 vol per cent (P <oooi).
Gases in the coronary venous blood (Table  4) did not show any significant change. The coronary arteriovenous difference did not increase.
Discussion
The principal cardiovascular response to intravenous administration of IO and 20 mg practolol in the i8 patients studied was a reduction in heart rate. This slowing of the heart rate alone was responsible for the moderate decrease in cardiac output. Jewitt, Burgess, and Shillingford (I970) made similar observations at comparable dosage levels. As oxygen consumption calculated indirectly from cardiac output and the arteriovenous oxygen difference was not significantly reduced, the fall in cardiac output was compensated by a proportionate increase in the arteriovenous oxygen difference, at the expense of the saturation ofmixed venous blood. The ejection time was lengthened to an insignificant extent. Jewitt et al. (I970) reported a significant increase in ejection time. The difference between these two results probably stems from the fact that some of the patients studied by these authors had an increased stroke volume.
It is worth while pointing out that the pulmonary arterial pressure did not increase. Sowton et al. (I968) made an identical observation in patients suffering from coronary heart disease. In the group of patients studied by Jewitt et al. (I970) pulmonary arterial pressure rose by a few mmHg. Since none of the patients studied in this trial was suffering from chronic respiratory disease, the pulmonary arterial diastolic pressure provides an accurate index for the filling pressure of the left heart. Bussmann et al. (1970) Sonnenblick et al. (I965a) observed that during adrenergic blockade the ejection rate increased even though the shift of the force-velocity curve indicated a reduction in contractility. The lowering of peak aortic dp/dt confirmed the negative inotropic effect of practolol. Nevertheless, this parameter, which varies in the same way as heart rate, did not permit one to determine whether the reduction in contractility arose solely from a fall in heart rate. Bussmann et al. (I970) have shown that in dogs, at least at doses of 2 mg/kg, and when the heart rate was held constant, left ventricular peak dp/dt was lowered, t-dp/dt increased, and the ratio between the LV dp/dt and the integrated isovolumetric pressure diminished, both known to reflect accurately the inotropic state of the myocardium (Siegel et al., I964 FIG. 3 Effect of practolol on external work index, stroke work index, aortic dp/dt, and mean systolic ejection rate per minute has been shown that this drug inhibits the reduction in arterial 02 tension which can be observed after administration of isoprenaline to asthmatic patients (Palmer et al., I969) . The coronary arteriovenous 02 difference in 5 patients where it could be measured was not increased. In this respect practolol had the same effect as propranolol, since Lewis and Brink (I968) This study provides evidence that practolol essentially had a negative chronotropic effect and that the reduction in contractility observed arose, for the most part, from a slowing in heart rate. An exact estimation of these effects may only be obtained from a further series of measurements made at constant heart rate.
The antiarrhythmic properties of practolol, especially on those rhythmic disturbances associated with adrenergic hyperactivity, demonstrate the undeniable therapeutic potential of the drug in acute myocardial infarction. The recent studies by Jewitt et al. (I969) , Vohra, Dowling, and Sloman (1970) 
